BAYCELLator consolidates expertise and know-how across various fields, facilitating a substantial and sustainable enhancement in collaboration concerning technologies (e.g. GMP-compliant production of cell products), testing procedures, clinically relevant relevant animal models, and regulatory matters. This, in turn, expedites the deployment and approval of innovative cell therapy approaches, making them accesible to a broader patient patient population with advanced tumor diseases. 

Under the BAYCELLator project, diverse immune cell-based therapeutic concepts can be efficiently compared, investigated, and implemented under realistic conditions. Projects benefit from synergies, particularly in clinically relevant animal model transfer and close cooperation with biotechnology companies. The project's envisaged GMP-compliant development steps allow for a rapid clinical translation, providing Bavaria with a competitive advantage as an innovation center for cellular therapies.

For participating biotech companies, the collaborative project offers the opportunity for faster technology transfer, increased scientific and economic visibility, improved recruitment of qualified personnel and the potential to generate innovative intellectual property (IP).